Trends in opioid prescribing in Australia: a systematic review*
Peter J. Donovan A B D , David Arroyo B , Champika Pattullo A and Anthony Bell B CA Department of Clinical Pharmacology, Royal Brisbane and Women’s Hospital, cnr Butterfield Street and Bowen Bridge Road, Herston, Qld 4029, Australia. Email: Champika.Pattullo@health.qld.gov.au
B The University of Queensland Faculty of Medicine and Biomedical Sciences, 288 Herston Road, Herston, Qld 4066, Australia. Email: davidarroyo1@yahoo.com
C The Wesley Hospital, 451 Coronation Drive, Auchenflower, Brisbane, Qld 4066, Australia. Email: dr.aj.bell@gmail.com
D Corresponding author. Email: peter.donovan@health.qld.gov.au
Australian Health Review 44(2) 277-287 https://doi.org/10.1071/AH18245
Submitted: 23 October 2018 Accepted: 15 April 2019 Published: 12 November 2019
Abstract
Objective This review systematically identified studies that estimated the prevalence of prescription opioid use in Australia, assessed the prevalence estimates for bias and identified areas for future research.
Methods Literature published after 2000 containing a potentially representative estimate of prescription opioid use in adults, in the community setting, in Australia was included in this review. Studies that solely assessed opioid replacement, illicit opioid usage or acute hospital in-patient use were excluded. Databases searched included PubMed, EMBASE, Web of Science and the grey literature.
Results The search identified 2253 peer-reviewed publications, with 34 requiring full-text review. Of these, 20 were included in the final qualitative analysis, in addition to four publications from the grey literature. Most studies included analysed prescription claims data for medicines dispensed via Australia’s national medicines subsidy scheme (the Pharmaceutical Benefits Scheme). Although data sources were good quality, all prevalence estimates were at least at moderate risk of bias, predominantly due to incompleteness of data or potential confounding. Included publications demonstrated a significant rise in opioid use up to 2017 (including a 15-fold increase in prescriptions dispensed over the 20 years to 2015), predominantly driven by a sharp rise in oxycodone use. Although opioid prescription numbers continue to escalate, usage, as measured by oral morphine equivalent per capita, may have plateaued since 2014. Codeine remains the most prevalently obtained opioid, followed by oxycodone and tramadol. There was a substantial delay (median 30 months; interquartile range 20–37 months) to publication of opioid usage data from time of availability.
Conclusions Australia has experienced a marked increase in opioid prescribing since the 1990s. Current published literature is restricted to incomplete, delayed and historical data, limiting the ability of clinicians and policy makers to intervene appropriately.
What is known about the topic? Opioid prescriptions in Australia have continued to increase since the 1990s and may be mirroring the epidemic being seen in the US.
What does this paper add? This paper systematically identifies all publications that have examined the prevalence of prescription opioid use in Australia since 2000, and only identified prevalence estimates that were at moderate or high risk of bias, and found significant delays to publication of these estimates.
What are the implications for practitioners? Because published literature on the prevalence of prescription opioid consumption is restricted to incomplete, delayed and historical data, the ability of clinicians and policy makers to appropriately intervene to curb prescription opioid use is limited. A national policy of real-time monitoring and reporting of opioid prescribing may support improvements in practice.
References
[1] Chen LH, Hedegaard H, Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999–2011. NCHS Data Brief 2014; 166 1–8.[2] Bonnie RJ, Ford MA, Phillips JK, editors, National Academies of Sciences, Engineering, Medicine. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. Washington, DC: The National Academies Press; 2017.
[3] Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths – United States, 2000–2014. MMWR Morb Mortal Wkly Rep 2016; 64 1378–82.
| Increases in drug and opioid overdose deaths – United States, 2000–2014.Crossref | GoogleScholarGoogle Scholar | 26720857PubMed |
[4] Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths – United States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016; 65 1445–52.
| Increases in drug and opioid-involved overdose deaths – United States, 2010–2015.Crossref | GoogleScholarGoogle Scholar | 28033313PubMed |
[5] Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care 2016; 54 901–6.
| The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013.Crossref | GoogleScholarGoogle Scholar | 27623005PubMed |
[6] Mercado MC, Sumner SA, Spelke MB, Bohm MK, Sugerman DE, Stanley C. Increase in drug overdose deaths involving fentanyl – Rhode Island, January 2012–March 2014. Pain Med 2018; 19 511–23.
| Increase in drug overdose deaths involving fentanyl – Rhode Island, January 2012–March 2014.Crossref | GoogleScholarGoogle Scholar | 28340233PubMed |
[7] Islam MM, McRae IS, Mazumdar S, Taplin S, McKetin R. Prescription opioid analgesics for pain management in Australia: 20 years of dispensing. Intern Med J 2016; 46 955–63.
| Prescription opioid analgesics for pain management in Australia: 20 years of dispensing.Crossref | GoogleScholarGoogle Scholar | 26602489PubMed |
[8] Karanges EA, Blanch B, Buckley NA, Pearson SA. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. Br J Clin Pharmacol 2016; 82 255–67.
| Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims.Crossref | GoogleScholarGoogle Scholar | 26991673PubMed |
[9] Leong M, Murnion B, Haber PS. Examination of opioid prescribing in Australia from 1992 to 2007. Intern Med J 2009; 39 676–81.
| Examination of opioid prescribing in Australia from 1992 to 2007.Crossref | GoogleScholarGoogle Scholar | 19460051PubMed |
[10] Australian Institute of Health and Welfare (AIHW). Opioid harm in Australia: and comparisons between Australia and Canada. Catalogue no. HSE 210. Canberra: AIHW; 2018. Available at: https://www.aihw.gov.au/reports/illicit-use-of-drugs/opioid-harm-in-australia/contents/summary [verified 6 March 2019].
[11] Arroyo D, Pattullo C, Donovan P, Bell A. Trends in opioid prescribing habits in Australia 2000–2017: a review. CRD42017076802. York, UK: PROSPERO; 2017. Available at: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017076802 [verified 16 January 2019].
[12] Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 e1000097
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.Crossref | GoogleScholarGoogle Scholar | 19753108PubMed |
[13] Drug Utilisation Sub-Committee. Opioid analgesics. Overview. Canberra: Department of Health, Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee; 2014.
[14] Department of Health. Australian statistics on Medicines 2015. 2015. Available at: http://www.pbs.gov.au/info/statistics/asm/asm-2015 [verified 2 July 2018].
[15] Pain and Policy Studies Group. Opioid consumption data – Australia. Indianapolis: The University of Indiana, Pain and Policy Studies Group; 2019. Available at: https://painpolicy.iu.edu/country/profile/australia [verified 28 October 2019].
[16] Australian Institute of Health and Welfare. National opioid pharmacotherapy statistics (NOPSAD) report no. 9. 2016. Available at: https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/national-opioid-pharmacotherapy-statistics-nopsad-2016/contents/summary [verified 20 July 2018].
[17] Australian Commission on Safety and Quality in Health Care. The first Australian atlas of healthcare variation. 2015. Available at: https://www.safetyandquality.gov.au/atlas/atlas-2015/ [verified 6 March 2019].
[18] Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012; 65 934–9.
| Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement.Crossref | GoogleScholarGoogle Scholar | 22742910PubMed |
[19] Blanch B, Gladstone E, Smolina K, Buckley NA, Karanges EA, Morgan SG, Sallie-Anne P. Benchmarking prescription drug access patterns in pharmaceutical claims: a method for identifying high and potentially harmful opioid use in Australia and Canada? J Pharm Health Serv Res 2017; 8 23–30.
| Benchmarking prescription drug access patterns in pharmaceutical claims: a method for identifying high and potentially harmful opioid use in Australia and Canada?Crossref | GoogleScholarGoogle Scholar |
[20] Blanch B, Pearson SA, Haber PS. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol 2014; 78 1159–66.
| An overview of the patterns of prescription opioid use, costs and related harms in Australia.Crossref | GoogleScholarGoogle Scholar | 24962372PubMed |
[21] Degenhardt L, Black E, Breen C, Bruno R, Kinner S, Roxburgh A, Fry C, Jenkinson R, Ward J, Fetherston J, Weekley J, Fischer J. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev 2006; 25 403–12.
| Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia.Crossref | GoogleScholarGoogle Scholar | 16939934PubMed |
[22] Degenhardt L, Bruno R, Ali R, Lintzeris N, Farrell M, Larance B. The introduction of a potentially abuse deterrent oxycodone formulation: early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. Drug Alcohol Depend 2015; 151 56–67.
| The introduction of a potentially abuse deterrent oxycodone formulation: early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.Crossref | GoogleScholarGoogle Scholar | 25910850PubMed |
[23] Degenhardt L, Gisev N, Cama E, Nielsen S, Larance B, Bruno R. The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. Pharmacoepidemiol Drug Saf 2016; 25 521–38.
| The extent and correlates of community-based pharmaceutical opioid utilisation in Australia.Crossref | GoogleScholarGoogle Scholar | 26781123PubMed |
[24] Gadzhanova S, Bell JS, Roughead EE. What analgesics do older people use prior to initiating oxycodone for non-cancer pain? A retrospective database study. Drugs Aging 2013; 30 921–6.
| What analgesics do older people use prior to initiating oxycodone for non-cancer pain? A retrospective database study.Crossref | GoogleScholarGoogle Scholar | 24002742PubMed |
[25] Gisev N, Pearson SA, Karanges EA, Larance B, Buckley NA, Larney S, Dobbins T, Blanch B, Degenhardt L. To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia? Pharmacoepidemiol Drug Saf 2018; 27 550–5.
| To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?Crossref | GoogleScholarGoogle Scholar | 29047196PubMed |
[26] Hollingworth SA, Gray PD, Hall WD, Najman JM. Opioid analgesic prescribing in Australia: a focus on gender and age. Pharmacoepidemiol Drug Saf 2015; 24 628–36.
| Opioid analgesic prescribing in Australia: a focus on gender and age.Crossref | GoogleScholarGoogle Scholar | 25845470PubMed |
[27] Karanges EA, Buckley NA, Brett J, Blanch B, Litchfield M, Degenhardt L, Pearson SA. Trends in opioid utilisation in Australia, 2006–2015: insights from multiple metrics. Pharmacoepidemiol Drug Saf 2018; 27 504–12.
| Trends in opioid utilisation in Australia, 2006–2015: insights from multiple metrics.Crossref | GoogleScholarGoogle Scholar | 29280224PubMed |
[28] Lalic S, Ilomaki J, Bell JS, Korhonen MJ, Gisev N. Prevalence and incidence of prescription opioid analgesic use in Australia. Br J Clin Pharmacol 2019; 85 202–15.
| Prevalence and incidence of prescription opioid analgesic use in Australia.Crossref | GoogleScholarGoogle Scholar | 30338545PubMed |
[29] Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesics and related harms in Australia. Med J Aust 2011; 195 280–4.
| Prescription of opioid analgesics and related harms in Australia.Crossref | GoogleScholarGoogle Scholar | 21895598PubMed |
[30] Roxburgh A, Burns L, Drummer OH, Pilgrim J, Farrell M, Degenhardt L. Trends in fentanyl prescriptions and fentanyl-related mortality in Australia. Drug Alcohol Rev 2013; 32 269–75.
| Trends in fentanyl prescriptions and fentanyl-related mortality in Australia.Crossref | GoogleScholarGoogle Scholar | 23442164PubMed |
[31] Wagemaakers FN, Hollingworth SA, Kreijkamp-Kaspers S, Tee EHL, Leendertse AJ, van Driel ML. Opioid analgesic use in Australia and the Netherlands: a cross-country comparison. Int J Clin Pharm 2017; 39 874–80.
| Opioid analgesic use in Australia and the Netherlands: a cross-country comparison.Crossref | GoogleScholarGoogle Scholar | 28608330PubMed |
[32] Berecki-Gisolf J, Hassani-Mahmooei B, Clapperton A, McClure R. Prescription opioid dispensing and prescription opioid poisoning: population data from Victoria, Australia 2006 to 2013. Aust N Z J Public Health 2017; 41 85–91.
| Prescription opioid dispensing and prescription opioid poisoning: population data from Victoria, Australia 2006 to 2013.Crossref | GoogleScholarGoogle Scholar | 27624336PubMed |
[33] Degenhardt L, Gilmour S, Shand F, Bruno R, Campbell G, Mattick RP, Larance B, Hall W. Estimating the proportion of prescription opioids that is consumed by people who inject drugs in Australia. Drug Alcohol Rev 2013; 32 468–74.
| 23889303PubMed |
[34] Hollingworth SA, Symons M, Khatun M, Loveday B, Ballantyne S, Hall WD, Najman JM. Prescribing databases can be used to monitor trends in opioid analgesic prescribing in Australia. Aust N Z J Public Health 2013; 37 132–8.
| Prescribing databases can be used to monitor trends in opioid analgesic prescribing in Australia.Crossref | GoogleScholarGoogle Scholar | 23551471PubMed |
[35] Islam MM, McRae IS, Mazumdar S, Simpson P, Wollersheim D, Fatema K, Butler T. Prescription opioid dispensing in New South Wales, Australia: spatial and temporal variation. BMC Pharmacol Toxicol 2018; 19 30
| Prescription opioid dispensing in New South Wales, Australia: spatial and temporal variation.Crossref | GoogleScholarGoogle Scholar | 29914572PubMed |
[36] Department of Health. Pharmaceutical Benefits Scheme collection of under co-payment data. 2018. Available at: http://www.pbs.gov.au/info/statistics/under-co-payment/under-co-payment-data [verified 2 July 2018].
[37] Mellish L, Karanges EA, Litchfield MJ, Schaffer AL, Blanch B, Daniels BJ, Segrave A, Sallie-Anne P. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Res Notes 2015; 8 634
| The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers.Crossref | GoogleScholarGoogle Scholar | 26526064PubMed |
[38] Department of Health. RPBS explanatory notes. 2018. Available at: https://www.pbs.gov.au/info/browse/rpbs/rpbs-explanatorynotes [verified 2 July 2018].
[39] Guy GP, Zhang K, Bohm MK, Losby J, Lewis B, Young R, Murphy LB, Dowell D. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017; 66 697–704.
| Vital signs: changes in opioid prescribing in the United States, 2006–2015.Crossref | GoogleScholarGoogle Scholar | 28683056PubMed |
[40] Department of Health. Codeine information hub. 2018. Available at: https://www.tga.gov.au/codeine-info-hub [verified 2 July 2018].
[41] Victoria State Government. SafeScript. 2018. Available at: https://www2.health.vic.gov.au/public-health/drugs-and-poisons/safescript [verified 4 July 2018].
[42] Sacco LN, Duff JH, Sarata AK. Prescription drug monitoring programs. Congressional Research Services. Report No. R42593. 2018. Available at: https://fas.org/sgp/crs/misc/R42593.pdf [verified 6 March 2019].
